Cochlear (COH.AX) Akcija Цена

Cochlear Цена

ASX·ZATVORENO
128,39
​
Tržište je zatvoreno

U poslednjih 19 godina prihod Cochlear rastao je 7,8 % godišnje i dostigao 2,33 Млрд AUD. Zarada po akciji rasla je 1,2 % godišnje u poslednjih 19 godina. Za Cochlear neto marža od 6,3 % je pala u odnosu na 17,6 % pre nekoliko godina. Po današnjoj ceni dividendni prinos iznosi otprilike 4,57 %. Odnos isplate je oko 95 % dobiti. Dividenda je rasla 6,5 % godišnje u poslednjih 19 godina. Konsenzusna 12-mesečna ciljana cena za Cochlear je 252,40 AUD, oko iznad kurs za 96,6 %. Od 19 analitičara 8 preporučuje kupovinu — ukupni konsenzus je Drži.

Cena akcije Cochlear

Pristupite ovim podacima preko Eulerpool API-ja

Cochlear poslovni model i analiza akcije

Cochlear Ltd je australijska kompanija za medicinsku tehnologiju osnovana 1981. godine od strane inženjera i profesora Graeme Clarka. Kompanija se specijalizuje za sisteme koklearnih implantata i druga slušna pomagala. Cochlear Ltd nudi dodatnu opremu, usluge i rehabilitacionu obuku za osobe sa oštećenjem sluha. Proizvodi kompanije namenjeni su kako deci, tako i odraslima sa različitim stepenom gubitka sluha. Cochlear Ltd posluje u različitim sektorima, uključujući sisteme koklearnih implantata, slušna pomagala i bežične dodatke i sisteme za strimovanje pod brendovima Nucleus® i Baha®. Sistemi Nucleus® koriste potpuno implantabilni koklearni implant i spoljni govorni procesor koji pretvaraju zvuk u električne signale koje mozak interpretira. Sistemi Baha® su koštano-ankeračani slušni uređaji namenjeni osobama sa jednostranim do umerenim oštećenjem sluha. Cochlear Ltd takođe pruža bežične dodatke i sisteme za strimovanje koji povezuju uređaje poput mobilnih telefona, televizora i plejera muzike sa slušnim pomagalima i koklearnim implanticima, čime se poboljšava performansa sluha i unapređuje socijalni život. Kompanija ima snažno globalno prisustvo, poslujući u više od 100 zemalja, sa sedištem u Australiji, višestrukim proizvodnim pogonima i istraživačkim centrima. Cochlear Ltd je dobila brojna priznanja i nagrade za svoje proizvode i usluge, a posvećena je istraživanju i razvoju novih terapija i tehnologija radi poboljšanja života osoba sa oštećenjem sluha.

Često postavljana pitanja o akciji Cochlear

Cochlear Ltd operates under a distinctive business model. As a global leader in the development and manufacturing of hearing solutions, the company primarily focuses on designing, producing, and marketing cochlear implant devices. Cochlear implants are electronic devices that provide a sense of sound to individuals with severe hearing loss or deafness. With a commitment to continuous innovation and superior quality, Cochlear Ltd offers a wide range of products and services that cater to the needs of patients, healthcare professionals, and hearing implant clinics worldwide. Through its robust business model, Cochlear Ltd aims to improve the lives of individuals with hearing challenges by providing cutting-edge and life-changing hearing solutions.

Cochlear Ltd is primarily active in the healthcare and medical device industries.

The main competitors of Cochlear Ltd in the market include major companies like Medtronic, Sonova Holding AG, and William Demant Holding A/S.

Cochlear Ltd is an Australian medical device company specializing in hearing implant solutions. Founded in 1981, it has a rich history and remarkable achievements in the field of implantable hearing devices. Cochlear is globally recognized for its groundbreaking advancements in the development and commercialization of cochlear implant technology. By providing solutions for people with profound hearing loss, Cochlear has improved the lives of millions worldwide. With a strong commitment to innovation and a dedicated team of experts, Cochlear remains at the forefront of the industry, continuously striving to enhance hearing experiences and transform lives through its state-of-the-art products and services.

Cochlear Ltd has achieved several significant milestones. One of the notable milestones includes the development and introduction of the world's first commercially successful cochlear implant in 1982. This breakthrough technology revolutionized the treatment of hearing loss for millions of people worldwide. Another key milestone for Cochlear Ltd was the successful launch of the Nucleus 6 Sound Processor, which offered enhanced hearing performance and wireless connectivity options. The company also made significant progress in expanding its global footprint, establishing subsidiaries and partnerships in different regions. Additionally, Cochlear Ltd received numerous industry recognitions and awards for its innovative products and contribution to the field of hearing healthcare.

Cochlear Ltd is primarily present in various countries and regions worldwide. The company operates in over 100 countries, including but not limited to Australia, the United States, Europe, Asia-Pacific, and Latin America. With its global presence, Cochlear Ltd has established itself as a leading provider of innovative hearing solutions and implantable hearing devices. Through its extensive network and collaborations, the company strives to enhance the lives of individuals with hearing loss across the world by providing advanced hearing technology and support.

Cochlear Ltd represents a strong set of values and corporate philosophy. The company is committed to improving the lives of people with hearing loss by providing innovative and reliable solutions. Cochlear believes in putting their customers first and delivering exceptional quality products and services. With a focus on continuous improvement, the company is dedicated to research and development to drive technological advancements in the field of hearing implants. Cochlear's corporate philosophy is centered around integrity, collaboration, and social responsibility. By embracing diversity and fostering a culture of inclusivity, Cochlear strives to make a positive impact on individuals and communities worldwide.

Analitičari trenutno postavljaju prosečnu ciljanu cenu 265,71 AUD za akciju Cochlear (medijana: 252,40 AUD), što znači +107,0 % u odnosu na poslednju cenu. Konsenzus se zasniva na 19 ocena.

19 analitičara trenutno ocenjuje akciju Cochlear: 9 preporučuje kupovinu, 9 držanje i 1 prodaju.

Po trenutnom kursu akcija Cochlear kotira 79,97 EUR (128,39 AUD).

Akcija Cochlear (COH.AX) kotira na 7 berze, uključujući: SIX (Zürich) (COH.SW), ASX (COH.AX), Frankfurt (OC5.F), München (OC5.MU), Düsseldorf (OC5.DU), Hamburg (OC5.HM).

Cochlear Ltd is a leading provider of innovative medical solutions for people with hearing loss. The company is headquartered in Sydney, Australia and operates in over 100 countries worldwide. Cochlear specializes in imitating the functionality of the human ear to provide a better hearing experience for those with hearing loss. They offer a wide range of products and services including cochlear implants, audioprocessors, cochlear replacement parts, and hearing aids. Cochlear implants are one of the company's main products, designed to help those with severe to profound hearing loss regain their ability to hear. The implant is an electronic device that bypasses the inner ear by sending signals directly to the auditory nerve. In addition to cochlear implants and audioprocessors, Cochlear also offers wireless accessory devices such as TV streamers to enhance the listening experience. They have a dedicated department for manufacturing hearing aids called "Cochlear Devices," which are designed for individuals with mild to moderate hearing loss. The company is always working on new technologies to improve the listening experience for individuals with hearing loss, including their latest innovation, the Cochlear sound processor, which utilizes artificial intelligence to automatically adapt to different environments for optimal sound quality. Cochlear provides a range of services to support their customers, including training and support for healthcare professionals who implant or adjust Cochlear devices. They collaborate with customers, clinics, research institutions, and universities to develop the latest advancements in technology to improve the lives of individuals with hearing loss. Cochlear's business model is focused on promoting health and well-being, providing innovative hearing device and implant technologies, and comprehensive services to ensure an excellent patient experience. They are committed to playing a leading role in the treatment of hearing loss and helping people worldwide overcome their hearing challenges.

prihod od Cochlear je 2,33 Млрд AUD. Ova cifra je zasnovana na trenutnim finansijskim podacima i odražava poslovne rezultate preduzeća.

dobit od Cochlear je 147,30 М AUD. Neto dobit pokazuje profitabilnost preduzeća nakon odbitka svih troškova.

Odnos cene i zarade (KGV) za Cochlear je trenutno 57,00. KGV poredi sadašnju cenu akcije sa zaradom po akciji i pomaže investitorima da procene valuaciju akcije Cochlear.

Odnos cene i prihoda (KUV) za Cochlear je trenutno 3,60. KUV poredi tržišnu kapitalizaciju sa godišnjim prihodima i služi kao metrika valuacije za akciju Cochlear.

Eulpool score kvaliteta za Cochlear je 4/10.

ISIN za Cochlear je AU000000COH5. ISIN (International Securities Identification Number) je globalno jedinstveni identifikator za hartije od vrednosti.

WKN za Cochlear je 898321. WKN (Wertpapierkennnummer) je šestocifreni nemački broj za identifikaciju hartija od vrednosti.

Ticker za Cochlear je COH.AX. Simbol tikera se koristi za trgovinu akcijama Cochlear na berzanskom tržištu.

Фер вредностTerminal
105,28 AUD
Над-/ПодцењеностTerminal
Адекватно вредна
Сектор
Индустрија
Медицинска опрема и понуде
Број акција
Запослени
Приход по запосленом
583.675,00 AUD
Раст прихода Ø5 година
Раст EBIT Ø5 година
Раст нето добити Ø5 година
Веб сајт cochlear.com
Земља
Аустралија
Валута
AUD
Јавна понуда
4. дец 1995.
ISIN
AU000000COH5
CUSIP
Q25953102
SEDOL
6211798
Тржишна капитализација
Опсег од 52 недеље
AAQS
5 / 10
PEG
7,37
P/E однос
P/Ee 2027
24,69
P/Ee 2028
22,51
P/Ee 2029
20,00
P/Ee 2030
17,77
P/Ee 2031
17,01
P/S
P/Se
3,53
EV/EBIT
27,98
P/B однос
4,84
ROE (Поврат на капитал)
ROA (Поврат на имовину)
ROCE (Поврат на ангажовани капитал)
ROIC (Поврат на уложени капитал)
8,46 %
Дивиденда
Прinos од дивиденде
4,57 %
Процењени принос од дивиденде
2,03 %
Стопа исплате
95,49 %
Раст дивиденде Ø5Y
12,55 %
Дивиденде по години
2
Дивиденда исплаћена од
30 година
Дивиденда није смањена од
5 година
Дивиденда повећана од
5 година
Порез на дивиденде
30,00 %
Zadnje ažurirano 10. окт 2026. 09:34

Cochlear Тикер

ASX · COH.AXDISELORF · OC5.DUFRANKFURT · OC5.FHAMBURG · OC5.HMMINHEN · OC5.MUOTC · CHEOFSIX · COH.SW

Cochlear FIGI

COH:AU · BBG000FT0MR1COH:AT · BBG000FT0N80OC5:GR · BBG000K9SM44OC5:GF · BBG000K9SMQ0OC5:GD · BBG000K9SN88OC5:GS · BBG000K9SPJ1OC5:GM · BBG000K9SQN4OC5:GB · BBG000K9SR07CHEOF:US · BBG000LSNP12CHEOF:UV · BBG000LSR175OC5:TH · BBG000TL2FZ7COH:AH · BBG0027TW9J9

Sve ključne metrke i detaljne analize Cochlear u dubinskoj analizi

Naša analiza akcija za akciju Cochlear uključuje važne finansijske pokazatelje kao što su prihod, profit, P/E odnos, P/S odnos, EBIT, kao i informacije o dividendama. Takođe, razmatramo aspekte poput akcija, tržišne kapitalizacije, dugova, kapitala i obaveza kompanije Cochlear. Ako tražite detaljnije informacije o ovim temama, na našim podstranicama vam nudimo opsežne analize: